Treatment of Overt Hepatic Encephalopathy in Adults with Chronic Liver Disease
Start lactulose 25 mL orally every 12 hours immediately, titrated to produce exactly 2–3 soft bowel movements per day, and continue it indefinitely after the first episode as secondary prophylaxis. 1, 2
Immediate Four-Pronged Management Approach
All patients with overt hepatic encephalopathy require simultaneous implementation of four critical steps 2, 3:
Stabilize altered consciousness and protect the airway: Patients with grade III–IV encephalopathy require immediate ICU admission with endotracheal intubation for airway protection. 2
Exclude alternative causes: Perform non-contrast head CT to rule out intracranial hemorrhage, drug intoxication, or structural lesions. 2
Identify and correct precipitating factors: This is the cornerstone of management—precipitating factors are present in 80–90% of episodes, and correcting them alone resolves hepatic encephalopathy in approximately 90% of cases. 1, 2, 3
Start empirical lactulose without delay: Do not wait for diagnostic confirmation. 2, 3
Systematic Search for Precipitating Factors
Failing to identify precipitating factors is the most common pitfall and leads to treatment failure in 90% of cases. 2 Evaluate systematically 2:
Gastrointestinal bleeding: Obtain CBC, digital rectal exam, stool occult blood test, and endoscopy when indicated; treat with blood transfusion, endoscopic hemostasis, and vasoactive medications.
Infection: Order CBC with differential, CRP, chest X-ray, urinalysis/culture, blood cultures, and diagnostic paracentesis; start empiric broad-spectrum antibiotics immediately if infection is suspected.
Constipation: Evaluate clinically and with plain abdominal radiography; manage with enemas or osmotic laxatives.
Dehydration: Hold diuretics and administer intravenous albumin or isotonic fluids after assessing skin turgor, vital signs, and basic metabolic panel.
Electrolyte disturbances: Correct sodium to 140–145 mmol/L along with potassium, magnesium, and phosphate abnormalities.
Renal dysfunction: Monitor BUN, serum creatinine, and electrolytes; adjust nephrotoxic medications and optimize volume status.
First-Line Pharmacologic Therapy
Lactulose is the first-choice treatment for all grades of overt hepatic encephalopathy and achieves clinical response in approximately 75% of patients. 1, 2, 3
Titrate to achieve exactly 2–3 soft bowel movements per day—not diarrhea. Underdosing leads to treatment failure; overdosing causes dehydration, hypernatremia, aspiration risk, and severe perianal irritation. 2
If oral intake is impossible, administer via nasogastric tube. 3
For patients unable to take oral or NG lactulose, use lactulose enema: 300 mL lactulose mixed with 700 mL water, administered 3–4 times daily, retained for at least 30 minutes. 2
Management by Encephalopathy Grade
Grades I–II (Mild-to-Moderate)
Manage on a medical ward with frequent mental status checks; ICU is preferred if available. 2
Transfer immediately to ICU if level of consciousness declines. 2
Avoid sedatives (benzodiazepines, opioids)—they worsen encephalopathy and have delayed clearance in liver failure. 2
Perform head CT to exclude intracranial hemorrhage. 2
Monitor glucose, potassium, magnesium, and phosphate levels closely. 2
Grades III–IV (Severe)
Patients with grade III–IV encephalopathy require immediate ICU admission with endotracheal intubation for airway protection—they cannot protect their airway and are at high risk of aspiration. 2
Elevate head of bed to 30°. 2
Minimize stimulation and Valsalva-type maneuvers. 2
Deliver lactulose via nasogastric tube if oral intake is impossible. 2
Treat seizures with phenytoin rather than benzodiazepines. 2
Use low-dose propofol only if sedation is absolutely necessary (may reduce cerebral blood flow). 2
For intracranial hypertension: give intravenous mannitol 0.5–1 g/kg as a bolus (repeat once or twice if serum osmolality < 320 mosm/L). 2
Cerebral edema occurs in 25–35% of grade III patients and 65–75% of grade IV patients. 2
Secondary Prophylaxis (Mandatory After First Episode)
Continue lactulose indefinitely after the first overt episode as secondary prophylaxis—this is a Grade I, strong recommendation from AASLD/EASL. 1, 2
Without secondary prophylaxis, 50–70% of patients experience recurrence within one year. 2
Adding Rifaximin for Recurrent Episodes
Add rifaximin 550 mg orally twice daily after a second episode or when recurrence occurs despite lactulose alone. 1, 2
Rifaximin plus lactulose reduces recurrence risk by 58% (22.1% vs 45.9%; NNT = 4) and lowers hospitalization risk by 31% (13.6% vs 22.6%; NNT = 9). 2, 4
Rifaximin combined with lactulose leads to faster recovery (76% vs 44% within 10 days; p = 0.004) and shorter hospital stay (5.8 days vs 8.2 days; p = 0.001). 2
Long-term rifaximin therapy (> 24 months) is safe and well tolerated. 2, 4
Rifaximin should not be used as monotherapy for acute overt encephalopathy—evidence quality does not support it as first-line. 2
Adjunctive Therapies for Refractory Cases
When lactulose ± rifaximin fails 1, 2, 3:
Intravenous albumin 1.5 g/kg/day combined with lactulose improves clinical recovery within 10 days (75% vs 53.3%; p = 0.03).
Intravenous L-ornithine L-aspartate (LOLA) 30 g/day lowers hepatic encephalopathy grade within 1–4 days (odds ratio 2.06–3.04) and shortens recovery time (1.92 days vs 2.50 days; p = 0.002). Oral LOLA is ineffective.
Oral branched-chain amino acids 0.25 g/kg/day may be used as adjuncts in patients unresponsive to standard therapy.
Neomycin 4–12 grams per day is an alternative, but long-term use carries risks of ototoxicity, nephrotoxicity, and neuromuscular blockade. 1, 5 Treatment should not exceed 5–6 days. 5
Metronidazole is an alternative choice but carries risks of peripheral neuropathy with prolonged use. 1, 2
Role of Ammonia Testing
A normal blood ammonia level should prompt reevaluation for alternative causes of altered mental status. 2
Elevated ammonia levels do not correlate with encephalopathy severity or prognosis and have limited utility beyond excluding hepatic encephalopathy when normal. 2
Nutritional Management
Do not restrict protein—this worsens malnutrition and sarcopenia, which are risk factors for hepatic encephalopathy. 2, 3
Provide moderate hyperalimentation with small, frequent meals throughout the day. 2, 3
Avoid fasting periods which worsen hepatic encephalopathy. 2, 3
Liver Transplantation Evaluation
Evaluate for liver transplantation after the first episode of overt hepatic encephalopathy. 2
Recurrent, intractable overt hepatic encephalopathy with liver failure is a formal indication for liver transplantation. 2, 3
Overall survival after an overt encephalopathy episode is 42% at 1 year and 23% at 3 years. 2
Special Clinical Scenarios
Post-TIPS Hepatic Encephalopathy
Neither rifaximin nor lactulose prevents post-TIPS hepatic encephalopathy better than placebo—routine prophylactic therapy is not recommended. 1, 3
If severe hepatic encephalopathy develops after TIPS, shunt diameter reduction can reverse it. 1
Spontaneous Portosystemic Shunts
- In patients with preserved liver function and recurrent overt hepatic encephalopathy, search for large spontaneous portosystemic shunts (e.g., splenorenal shunts) that may be amenable to embolization. 1, 3
Critical Pitfalls to Avoid
Failing to systematically search for precipitating factors, which cause 90% of cases. 2
Not titrating lactulose adequately to achieve exactly 2–3 stools per day. 2
Confusing hepatic encephalopathy with other causes of altered mental status without exclusion of alternative diagnoses. 2
Not initiating secondary prophylaxis after the first episode. 2
Relying exclusively on ammonia levels for diagnosis—they lack diagnostic, staging, or prognostic value. 2
Using benzodiazepines or opioids, which have delayed clearance and exacerbate encephalopathy. 2